Updates on HER2-Directed ADCs Across Solid Tumors : Episode 17
Opinion
Video
Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy
Author(s):
Ronan Kelly, MD, MBA, offers insights on trastuzumab deruxtecan approval as tumor-agnostic HER2-directed therapy.
EP: 1.Assessing HER2 Status Across Tumor Types
EP: 2.ADCs Targeting HER2+ Breast Cancer
EP: 3.ADCs Targeting HER2+ Gynecologic Cancers
EP: 4.Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06
EP: 5.ADCs Targeting GI Cancers
EP: 6.ADCs Targeting HER2+ Lung Cancer
EP: 7.Impact of ADCs on Brain Metastases
EP: 8.ADCs Targeting HER2+ GU Cancers
EP: 9.Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types
EP: 10.The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines
EP: 11.Managing ILD and Pneumonitis Risk From ADCs
EP: 12.Managing Toxicities in Short- and Long-Term Treatment with ADCs
EP: 13.Managing Hematologic AEs Associated with ADC Treatments
EP: 14.Management of Emetogenicity of Antibody-Drug Conjugates
EP: 15.ADC Sequencing
EP: 16.Emerging ADCs in Development
Now Viewing
EP: 17.Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy
EP: 18.The Future for HER2-Directed ADCs
EP: 19.Key Takeaways and Closing Thoughts on ADCs
Related Videos
Related Content
